Twice-yearly lenacapavir: A milestone for HIV prevention in young African women
- PMID: 39395403
- DOI: 10.1016/j.medj.2024.08.008
Twice-yearly lenacapavir: A milestone for HIV prevention in young African women
Abstract
The PURPOSE 1 trial1 demonstrated that after 52 weeks, no cisgender women acquired HIV infection after receiving subcutaneous twice-yearly lenacapavir. HIV incidence with lenacapavir was significantly lower than HIV incidence with daily oral emtricitabine/tenofovir alafenamide (F/TAF) or daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF). It is the first pre-exposure prophylaxis regimen with 100% efficacy in young women.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no conflicts of interest.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical